Eli Lilly & Co. (NYSE: LLY) announced positive topline results from the Phase 3 TRIUMPH‑4 trial evaluating retatrutide in adults with obesity/overweight and knee osteoarthritis, without diabetes. Both doses (9 mg and 12 mg) met all primary and key secondary endpoints at 68 weeks, delivering up to 28.7% average weight loss (71.2 lbs) and up to 4.5‑point reduction in WOMAC pain scores (75.8%).
Subcutaneous injection (9 mg and 12 mg doses studied)
Indication
Obesity/overweight with knee osteoarthritis (non‑diabetic)
Regulatory Status
Phase 3 TRIUMPH‑4 completed; submission planned by end‑2025
Broader Pipeline
Phase 3 trials ongoing in T2D, OSA, chronic back pain, MASLD, CV/renal outcomes
Market Opportunity
Metric
Value
Implication
Global Obesity Market
$35 billion (2025)
Projected $60 billion by 2030
Osteoarthritis Comorbidity
250 million adults globally
High unmet need for weight‑pain dual therapy
Retatrutide Peak Sales
$15‑20 billion (global estimate)
If approved across multiple indications
Competitive Position
Triple agonist vs. GLP‑1 mono/dual agents
Potential best‑in‑class efficacy
Forward‑Looking Statements This brief contains forward‑looking statements regarding retatrutide’s regulatory submission timeline, market projections, and broader development program. Actual results may differ due to regulatory delays, competitive responses, or safety profile changes.-Fineline Info & Tech
By Fineline Cube 